Indapamide Market Trends, Future Outlook, COVID-19 Impact Analysis, Forecast 2022-2028
The global
indapamide market is estimated to grow significantly at a CAGR of over 2.0%
during the forecast period. A significant rise in the incidences of high blood
pressure (hypertension) and congestive heart failure is primarily contributing
to the growth of the market. High blood pressure affects approximately a third
of the adult population across the globe and is the most common cause of
CVD-related mortalities. As per the data published by the American Health
Association (AHA) in January 2018, 103 million US adults were suffering from
high blood pressure, which is nearly half of all adults in the US.
To learn more about this report request a sample
copy @ https://www.omrglobal.com/request-sample/indapamide-market
The global
indapamide market is segmented on the basis of product and application. Based
on the product, the market is bifurcated into 1.25 mg indapamide and 2.5 mg
indapamide. Among these, the market for 1.25 mg medicine held a significant
market share owing to the extensive application of the drug in treating high
blood pressure or hypertension. Based on the application, the market is
segmented into high blood pressure, heart failure, and others. The high blood pressure
segment is projected to have a significant share in the market. Growing
incidence of hypertension is contributing to the segmental growth as indapamide
drugs are significantly used to treat hypertension while reducing the risk of
developing serious heart conditions.
Geographically,
the study of the global indapamide market covers the analysis of four major
regions including North America (the US and Canada), Europe (UK, Germany,
Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India,
and Rest of Asia-Pacific), and the Rest of the World. The companies which are
contributing to the growth of the global indapamide market include ANI
Pharmaceuticals, Inc., Apotex Inc., Krka Group, Glenmark Pharmaceuticals Ltd,
Les Laboratoires Servier, SAS, Sandoz International Gmbh (A Novartis Division),
Taj Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., and Teva Pharmaceutical
Industries Ltd. Various growth strategies are adopted by the market players to
expand their market share and gain a competitive advantage. For instance, in
January 2020, ANI Pharmaceuticals, Inc., acquired the US portfolio of 23
generic products from Amrigen Pharmaceuticals Ltd.
Indapamide Market- Segmentation
By
Product
·
1.25 MG
·
2.5 MG
By
Application
·
High Blood Pressure
·
Heart Failure
·
Others
A full report of Indapamide Market is available
at: https://www.omrglobal.com/industry-reports/indapamide-market
Indapamide Market– Segment by Region
North America
·
United States
·
Canada
Europe
·
Germany
·
United Kingdom
·
France
·
Spain
·
Italy
·
Rest of Europe
Asia-Pacific
·
China
·
Japan
·
India
·
Rest of
Asia-Pacific
Rest of the World
·
Middle East &
Africa
·
Latin America
Company Profiles
·
ANI
Pharmaceuticals, Inc.
·
Apotex Inc.
·
BioindustriaL.I.M.
S.p.A.
·
Glenmark
Pharmaceuticals Ltd.
·
Grupo Azevedos
·
Krka Group
·
Laboratori Baldacci
S.p.A.
·
Merck KGaA
·
Mylan N.V.
·
Preferred
Pharmaceuticals, Inc
·
Sandoz
International GmbH
·
SanisHealth Inc.
·
Sanofi S.A.
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more
than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after
purchasing your report.
About Orion Market Research
Orion
Market Research (OMR) is a market research and consulting company known for its
crisp and concise reports. The company is equipped with an experienced team of
analysts and consultants. OMR offers quality syndicated research reports,
customized research reports, consulting and other research-based services.
Media Contact:
Contact
Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no:
+91 780-304-0404
Company
Name: Orion Market Research
0 Comments